Oruka Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Oruka Therapeutics, Inc. (ORKA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 99.02% for the 11-month period ending 2024-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-03-12
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-09-30 was 99.00%.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2012-06-30 was 0.00%, a 100.00% decline year-over-year.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2011-06-30 was 110.00%.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 107.00%, a 13.83% increase from fiscal 2021.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2021 was 94.00%, a 2.08% decline from fiscal 2020.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2020 was 96.00%.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2018 was 90.00%, a 23.29% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 8 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 11 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|---|
| 2024-12-31 | 99.02% 10-K · filed 2026-03-12 | |||||
| 2024-09-30 | 99.00% 10-Q · filed 2024-11-13 | 99.00% 10-Q · filed 2024-11-13 | ||||
| 2022-12-31 | 107.00% 10-K · filed 2024-02-01 | |||||
| 2021-12-31 | 94.00% 10-K · filed 2023-02-24 | |||||
| 2020-12-31 | 96.00% 10-K · filed 2022-03-14 | |||||
| 2018-12-31 | 90.00% 10-K · filed 2020-02-18 | |||||
| 2017-12-31 | 73.00% 10-K · filed 2019-02-27 | |||||
| 2016-12-31 | 72.00% 10-K · filed 2018-03-22 | |||||
| 2015-12-31 | 89.00% 10-K · filed 2017-03-21 | |||||
| 2014-12-31 | 94.00% 10-K · filed 2016-03-17 | |||||
| 2013-12-31 | 96.00% 10-K · filed 2015-03-19 | |||||
| 2012-12-31 | 108.00% 10-K · filed 2014-03-20 | |||||
| 2012-09-30 | 108.00% 10-Q · filed 2012-11-13 | |||||
| 2012-06-30 | 0.00% 10-Q · filed 2012-08-13 | 108.00% 10-Q · filed 2012-08-13 | ||||
| 2011-12-31 | 110.00% 10-K · filed 2013-03-21 | |||||
| 2011-09-30 | 110.00% 10-Q · filed 2012-11-13 | |||||
| 2011-06-30 | 110.00% 10-Q · filed 2012-08-13 | 110.00% 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |